ArticleDisease models & mechanisms2018
Collagen COL22A1 maintains vascular stability and mutations in
Article in Disease models & mechanisms, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Intracranial Aneurysm-Associated COL22A1 Variants Impair Cerebrovascular Structure and Barrier Integrity in Zebrafish.International journal of molecular sciences · 2026Article
- Establishing PDK1-based prognostic biomarkers and identifying targeted inhibitors for glioma prognosis and therapy.BMC neurology · 2026Article
- Ageing-related structural and cellular alterations in the mouse muscle-tendon junction.Biogerontology · 2026Article
- Location and aetiology are determinants of fibroblast activation and heterogeneity in the failing human heart.Genome medicine · 2025Article
- COL22A1 expression identifies aggressive glioma and independently predicts survival through integrated multiomics and clinical validation.Discover oncology · 2025Article
- Malignant progression of MES-like cells mediated by COL22A1 in the spatial heterogeneity of glioblastoma.Discover oncology · 2025Article
- Targeting collagen to optimize cancer immunotherapy.Experimental hematology & oncology · 2025Review
- Bioinformatics analysis to identify key invasion related genes and construct a prognostic model for glioblastoma.Scientific reports · 2025Article
- Construction and validation of a novel prognostic model with palmitoylation-related genes for glioblastoma.Translational cancer research · 2024Article
- Prognosis and immunoinfiltration analysis of angiogene-related genes in grade 4 diffuse gliomas.Aging · 2023Article
- A single-cell transcriptional atlas reveals resident progenitor cell niche functions in TMJ disc development and injury.Nature communications · 2023Article
- AreInternational journal of environmental research and public health · 2022Article
- Article
- Review
- The genomic basis of high-elevation adaptation in wild house mice (Mus musculus domesticus) from South America.Genetics · 2022Article
- Phenotyping Zebrafish Mutant Models to Assess Candidate Genes Associated with Aortic Aneurysm.Genes · 2022Article
- EMILIN2 is associated with prognosis and immunotherapy in clear cell renal cell carcinoma.Frontiers in genetics · 2022Article
- A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.Frontiers in immunology · 2022Article
- Decreased Trabecular Bone Mass inCells · 2021Article
- Collagen Binding Proteins of Gram-Positive Pathogens.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Collagen XXII (COL22A1) is a quantitatively minor collagen, which belongs to the family of fibril-associated collagens with interrupted triple helices. Its biological function has been poorly understood. Here, we used a genome-editing approach to generate a loss-of-function mutant in zebrafish
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.